Global Fund to make first grants in April

This article is more than 23 years old. Click here for more recent articles on this topic

The first directors have now been appointed to the Global Fund to fight AIDS, TB and Malaria, which has just finished its first meeting in Geneva, Switzerland. Funding criteria have been announced, which clearly follow the ideas developed by the Global Fund's Transitional Working Group. The first round of grants is promised for April when the Global Fund will be meeting again, in New York.

The basic principle of the Global Fund is to support priority-setting within and by the people most directly affected by the three diseases, and not to impose those priorities on them. This has been strongly supported by the Stop AIDS Campaign in the UK but goes against calls from some activists for a minimum proportion of the funding to be reserved for antiretrovirals to treat HIV.

The Global Fund is set up as a "public-private partnership" whose board reflects a range of different interests. There are seven governmental donors, seven governments representing countries likely to draw on the Fund, two non-governmental organisations (one from the North, one from the South), two private sector organisations (representing Foundations and business), and non-voting memberships reserved for a person living with AIDS (or, in theory, TB or malaria), WHO and UNAIDS.

Glossary

malaria

A serious disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. People who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. 

UNAIDS

The Joint United Nations Programme on HIV/AIDS (UNAIDS) brings together the resources of ten United Nations organisations in response to HIV and AIDS.

representative sample

Studies aim to give information that will be applicable to a large group of people (e.g. adults with diagnosed HIV in the UK). Because it is impractical to conduct a study with such a large group, only a sub-group (a sample) takes part in a study. This isn’t a problem as long as the characteristics of the sample are similar to those of the wider group (e.g. in terms of age, gender, CD4 count and years since diagnosis).

“The Fund is an unprecedented cooperative effort to combat the world’s

deadliest epidemics,” said Paul Ehmer, Team Leader of the Secretariat, in the Global Fund's news release announcing the outcome of its first meeting.

“Today, we are taking a major step forward, moving rapidly to get these

resources to the people that need them most. This is not just a matter of

caring and compassion -- it is economically wise as well. The diseases we

are addressing have a terrible impact both on human lives and on economic

development."

"A report (Macroeconomics and health: investing in health for economic development) released recently by leading economists and health experts reaffirms that healthy people are essential to a nation’s economic prosperity."

"The Fund will finance plans developed through country partnerships in

severely affected countries as well as in areas with growing epidemics. It

will also support plans in countries that have demonstrated the highest

level political commitment to eradicating these diseases. Its approach

will be integrated and balanced, covering prevention, treatment, and care

and support in dealing with the three diseases.

"Proposals will be funded rapidly, with minimum red tape, but with enough

safeguards to make sure funds are used responsibly and effectively. Also,

the Fund will finance projects that are most likely to clearly demonstrate

measurable success.

President George W Bush yesterday pledged US $200 million for the Global Fund in 2003, disappointing many activists who had been led to expect that US contributions would rise above the $200 million committed for this year. To date, including this announcement, industrialised and developing countries, corporations, foundations and individuals have pledged some US$1.9 billion to the Fund, of which up to US$700 million are expected to be granted in 2002.

The Fund says that while this is an important start, far more resources are needed. The Fund’s aim is to attract significant additional resources that will increase the pool of money already available to fight AIDS, tuberculosis and malaria.

“To be able to responsibly spend millions of dollars in a way that will

make a measurable difference takes time,” said Mr Ehmer. “We must get it

right.”

How the Global Fund is Administered

A unique feature of the Global Fund is its composition, which includes Non-Governmental Organisations (NGOs) and private sector interests as of right.

Donor countries represented on the Board are France, Italy, Japan, Sweden,

the UK, the US and the European Commission. Some of these seats have

alternates and will rotate among countries.

Similarly, the seven developing countries on the Board include China, Brazil, Nigeria, Pakistan, Thailand, Uganda, Ukraine.

The private sector is represented by the Gates Foundation (on behalf of Foundations) and Anglo-American, the mining company with extensive business interests in southern Africa, which has recently committed itself to health benefits including access to antiretroviral treatment for its HIV positive employees. Contrary to some published statements, this position was not awarded to a pharmaceutical company although senior pharmaceutical company representatives did offer to serve.

The NGO representatives, with full voting rights, are Millie Katana, a woman living with HIV, representing the Health Rights Action Group of Uganda, and Dr Christoph Benn who is Head of the Department for Health Policy and Studies with the German Institute for Medical Mission.

There are two alternate NGO representatives, namely Fidon R Mwombeki who is the General Secretary of the Northwestern Diocese Evangelical Lutheran Church in Tanzania, and Dr Peter Poore, a health adviser associated with Save the Children in the UK.

In addition to regular Board members, the Joint United Nations Programme

on HIV/AIDS (UNAIDS) and the World Health Organization (WHO), along with

the World Bank, which handles the Global Fund’s finances, hold ex-officio

non-voting seats on the Board. The Board’s composition includes a person

living with or affected by HIV/AIDS, TB or malaria, also in a non-voting

seat. This is occupied by Philippa Lawson, an active member of the International Community of Women with HIV (ICW), based in the USA (Charles Roy, the Executive Director of the AIDS Committee of Toronto is an alternate representative).

A small Secretariat located in Geneva manages the Global

Fund’s work and recruitment of the permanent executive head and staff is

beginning. Meantime, an interim Secretariat is being staffed by

secondments from UN organizations and governments.

Mobilizing additional public and private resources will be a key goal for

the Fund. The Fund’s second board meeting will take place towards the end

of April in New York.